Zydus Lifesciences has planned to launch Semaglutide Injection under the brand names -- Semaglyn, Mashema and Alterme, upon Semaglutide patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and Obesity.

A critical differentiator of Zydus’ Semaglutide offering will be its novel, indigenously developed drug-delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device. This technology allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximizing convenience and drastically reducing the overall cost of therapy.

Zydus has exclusive rights to this novel device, which will be able to deliver all strengths approved for Type 2 Diabetes Mellitus and Obesity. The pen will also be reusable bringing in greater affordability for the patients.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.